Diabetes, endothelial dysfunction, and vascular repair: What should a diabetologist keep his eye on?

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Altabas, V ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; EZETIMIBE; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; METFORMIN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PITAVASTATIN; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SITAGLIPTIN; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; VOGLIBOSE; ZOFENOPRIL;

ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; COMORBIDITY; DIABETES MELLITUS; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ESSENTIAL HYPERTENSION; EXERCISE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR BIOLOGY; VASCULAR SURGERY;

EID: 84930676966     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/848272     Document Type: Review

References (126)

1. M. C. Riddle, "Glycemic control and cardiovascular mortality," Current Opinion in Endocrinology, Diabetes & Obesity, vol. 18, no. 2, pp. 104-109, 2011.
2. L. G. Mellbin, M. Anselmino, and L. Rydén, "Diabetes, prediabetes and cardiovascular risk," European Journal of Cardiovascular Prevention and Rehabilitation, vol. 17, supplement 1, pp. S9-S14, 2010.
3. I. Martín-Timón, C. Sevillano-Collantes, A. Segura-Galindo, andF. J. delCañizo-Gómez, "Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?" World Journal of Diabetes, vol. 5, no. 4, pp. 444-470, 2014.
4. R. Stöhr and M. Federici, "Insulin resistance and atherosclerosis: convergence between metabolic pathways and inflammatory nodes," Biochemical Journal, vol. 454, no. 1, pp. 1-11, 2013.
5. M. M. Polovina and T. S. Potpara, "Endothelial dysfunction in metabolic and vascular disorders," Postgraduate Medicine, vol. 126, no. 2, pp. 38-53, 2014.
6. Y. Imai, A. D. Dobrian, J. R. Weaver et al., "Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease," Diabetes, Obesity and Metabolism, vol. 15, supplement 3, pp. 117-129, 2013.
7. J. L. Johnson, "Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis," Cardiovascular Research, vol. 103, no. 4, pp. 452-460, 2014.
8. J. F. Bentzon, F. Otsuka, R. Virmani, and E. Falk, "Mechanisms of plaque formation and rupture," Circulation Research, vol. 114, no. 12, pp. 1852-1866, 2014.
9. Z. Sun, "Atherosclerosis and atheroma plaque rupture: normal anatomy of vasa vasorum and their role associated with atherosclerosis," The Scientific World Journal, vol. 2014, Article ID285058, 6 pages, 2014.
10. A. Sannino, L. Brevetti, G. Giugliano et al., "Non-invasive vulnerable plaque imaging: how do we know that treatment works?" European Heart Journal-Cardiovascular Imaging, vol. 15, no. 11, pp. 1194-1202, 2014.
11. J. E. Feig, "Regression of atherosclerosis: insights from animal and clinical studies," Annals of Global Health, vol. 80, no. 1, pp. 13-23, 2014.
12. R. W. Wissler and D. Vesselinovitch, "Brief overview of the mounting evidence that atherosclerosis is both preventable and reversible," Journal of Clinical Apheresis, vol. 4, no. 2-3, pp. 52-58, 1988.
13. P. Constantinides, "Overview of studies on regression of atherosclerosis," Artery, vol. 9, no. 1, pp. 30-43, 1981.
14. P. S. S. Lee and K. K. Poh, "Endothelial progenitor cells in cardiovascular diseases,"World Journal of Stem Cells, vol. 6, no. 3, pp. 355-366, 2014.
15. L. Zhang and Q. Xu, "Stem/progenitor cells in vascular regeneration," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 34, no. 6, pp. 1114-1119, 2014.
16. E. Mannarino and M. Pirro, "Endothelial injury and repair: a novel theory for atherosclerosis," Angiology, vol. 59, no. 2, supplement, pp. 69S-72S, 2008.
17. C. Besler, C. Doerries, G. Giannotti, T. F. Lüscher, and U. Landmesser, "Pharmacological approaches to improve endothelial repair mechanisms," Expert Review of CardiovascularTherapy, vol. 6, no. 8, pp. 1071-1082, 2008.
18. K.-H. Yiu and H.-F. Tse, "Specific role of impaired glucose metabolism and diabetes mellitus in endothelial progenitor cell characteristics and function," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 6, pp. 1136-1143, 2014.
19. P. Rajendran, T. Rengarajan, J. Thangavel et al., "The vascular endothelium and human diseases," International Journal of Biological Sciences, vol. 9, no. 10, pp. 1057-1069, 2013.
20. J.XuandM.H. Zou, "Molecular insights andtherapeutic targets for diabetic endothelial dysfunction," Circulation, vol. 120, no. 13, pp. 1266-1286, 2009.
21. C. Aalkjær,D. Boedtkjer, andV.Matchkov, "Vasomotion-what is currently thought?" Acta Physiologica, vol. 202, no. 3, pp. 253-269, 2011.
22. J. E. Deanfield, J. P. Halcox, and T. J. Rabelink, "Endothelial function and dysfunction: testing and clinical relevance," Circulation, vol. 115, no. 10, pp. 1285-1295, 2007.
23. R. H. Böger, "The pharmacodynamics of L-arginine," Alternative Therapies in Health and Medicine, vol. 20, no. 3, pp. 48-54, 2014.
24. J. Lei, Y. Vodovotz, E. Tzeng, and T. R. Billiar, "Nitric oxide, a protective molecule in the cardiovascular system," Nitric Oxide, vol. 35, pp. 175-185, 2013.
25. M. Félétou and P. M. Vanhoutte, "Endothelium-derived hyperpolarizing factor: where are we now?" Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 6, pp. 1215-1225, 2006.
26. L. Stoner, M. L. Erickson, J. M. Young et al., "There's more to flow-mediated dilation than nitric oxide," Journal of Atherosclerosis andThrombosis, vol. 19, no. 7, pp. 589-600, 2012.
27. A. J.Donato,G. L. Pierce,L.A.Lesniewski, andD.R.Seals, "Role of NFkappaB in age-related vascular endothelial dysfunction in humans," Aging, vol. 1, no. 8, pp. 678-680, 2009.
28. I. Sudano, S. Roas, and G. Noll, "Vascular abnormalities in essential hypertension," Current Pharmaceutical Design, vol. 17, no. 28, pp. 3039-3044, 2011.
29. M. Pacurari, R. Kafoury, P. B. Tchounwou, and K. Ndebele, "The renin-angiotensin-aldosterone system in vascular inflammation and remodeling," International Journal of Inflammation, vol. 2014, Article ID689360, 13 pages, 2014.
30. R. Madonna and R. de Caterina, "Cellular and molecular mechanisms of vascular injury in diabetes-part II: cellular mechanisms and therapeutic targets," Vascular Pharmacology, vol. 54, no. 3-6, pp. 75-79, 2011.
31. A. C. Roberts and K. E. Porter, "Cellular and molecular mechanisms of endothelial dysfunction in diabetes," Diabetes& Vascular Disease Research, vol. 10, no. 6, pp. 472-482, 2013.
32. M. M. Hartge, T. Unger, and U. Kintscher, "The endothelium and vascular inflammation in diabetes," Diabetes and Vascular Disease Research, vol. 4, no. 2, pp. 84-88, 2007.
33. H. A. R. Hadi and J. A. Al Suwaidi, "Endothelial dysfunction in diabetes mellitus," Vascular Health and Risk Management, vol. 3, no. 6, pp. 853-876, 2007.
34. P. Geraldes and G. L. King, "Activation of protein kinase C isoforms and its impact on diabetic complications," Circulation Research, vol. 106, no. 8, pp. 1319-1331, 2010.
35. C. Manrique, G. Lastra, and J. R. Sowers, "New insights into insulin action and resistance in the vasculature," Annals of the New York Academy of Sciences, vol. 1311, no. 1, pp. 138-150, 2014.
36. X. F. Liu, J.Q.Yu, R. Dalan, A. Q. Liu, andK.Q. Luo, "Biological factors in plasma from diabetes mellitus patients enhance hyperglycaemia and pulsatile shear stress-induced endothelial cell apoptosis," Integrative Biology, vol. 6, no. 5,pp. 511-522, 2014.
37. L. Piconi, L. Quagliaro, R. Assaloni et al., "Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction," Diabetes/ Metabolism Research and Reviews, vol. 22, no. 3, pp. 198-203, 2006.
38. A. Avogaro, M. Albiero, L.Menegazzo, S. de Kreutzenberg, and G. P. Fadini, "Endothelial dysfunction in diabetes: the role of reparatory mechanisms," Diabetes Care, vol. 34, supplement 2, pp. S285-S290, 2011.
39. J. A. McClung, N. Naseer, M. Saleem et al., "Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c," Diabetologia, vol. 48, no. 2, pp. 345-350, 2005.
40. S. Nomura, "Dynamic role of microparticles in type 2 diabetes mellitus," Current Diabetes Reviews, vol. 5, no. 4, pp. 245-251, 2009.
41. A. A. Alsheikh-Ali, G. D. Kitsios, E. M. Balk, J. Lau, and S. Ip, "The vulnerable atherosclerotic plaque: scope of the literature," Annals of Internal Medicine, vol. 153, no. 6, pp. 387-395, 2010.
42. V. J. Dzau, M. Gnecchi, A. S. Pachori, F. Morello, and L. G. Melo, "Therapeutic potential of endothelial progenitor cells in cardiovascular diseases," Hypertension, vol. 46, no. 1, pp. 7-18, 2005.
43. T. Asahara, A. Kawamoto, and H. Masuda, "Concise review: circulating endothelial progenitor cells for vascular medicine," Stem Cells, vol. 29, no. 11, pp. 1650-1655, 2011.
44. T. Resch, A. Pircher, C. M. Kähler, J. Pratschke, and W. Hilbe, "Endothelial progenitor cells: current issues on characterization and challenging clinical applications," Stem Cell Reviews and Reports, vol. 8, no. 3, pp. 926-939, 2012.
45. B. Özüyaman, P. Ebner, U. Niesler et al., "Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of hematopoietic stem cells," Thrombosis and Haemostasis, vol. 94, no. 4, pp. 770-772, 2005.
46. A. Zampetaki, J. P. Kirton, and Q. Xu, "Vascular repair by endothelial progenitor cells," Cardiovascular Research, vol. 78, no. 3, pp. 413-421, 2008.
47. R. M. Cubbon, M. B. Kahn, and S. B. Wheatcroft, "Effects of insulin resistance on endothelial progenitor cells and vascular repair," Clinical Science, vol. 117, no. 5, pp. 173-190, 2009.
48. R. C. Rennert, M. Sorkin, R. K. Garg, and G. C. Gurtner, "Stem cell recruitment after injury: lessons for regenerative medicine," Regenerative Medicine, vol. 7, no. 6, pp. 833-850, 2012.
49. S.-W. Youn, S.-W. Lee, J. Lee et al., "COMP-Ang1 stimulates HIF-1α-mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment," Blood, vol. 117, no. 16, pp. 4376-4386, 2011.
50. X. Liu, B. Duan, Z. Cheng et al., "SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion," Protein and Cell, vol. 2, no. 10, pp. 845-854, 2011.
51. S.Wassmann, N.Werner, T. Czech, and G. Nickenig, "Improvement of endothelial function by systemic transfusion of vascular progenitor cells," Circulation Research, vol. 99, no. 8, pp. e74-e83, 2006.
52. J. I. Rotmans, J. M. M. Heyligers, H. J. M. Verhagen et al., "In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts," Circulation, vol. 112, no. 1, pp. 12-18, 2005.
53. G. P. Fadini, S. Sartore, C. Agostini, and A. Avogaro, "Significance of endothelial progenitor cells in subjects with diabetes," Diabetes Care, vol. 30, no. 5, pp. 1305-1313, 2007.
54. C. G. Egan, R. Lavery, F. Caporali et al., "Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes," Diabetologia, vol. 51, no. 7, pp. 1296-1305, 2008.
55. G. P. Fadini, S. Sartore, M. Schiavon et al., "Diabetes impairs progenitor cell mobilisation after hindlimb ischaemiareperfusion injury in rats," Diabetologia, vol. 49, no. 12, pp. 3075-3084, 2006.
56. A. Aicher, C. Heeschen, and S. Dimmeler, "The role of NOS3 in stem cell mobilization," Trends in Molecular Medicine, vol. 10, no. 9, pp. 421-425, 2004.
57. C. V. Desouza, F. G. Hamel, K. Bidasee, and K. O'Connell, "Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction," Diabetes, vol. 60, no. 4, pp. 1286-1294, 2011.
58. T. J. Rabelink, H. C. de Boer, E. J. P. de Koning, and A.-J. van Zonneveld, "Endothelial progenitor cells: more than an inflammatory response?" Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 834-838, 2004.
59. H. Tilg and A. R. Moschen, "Inflammatory mechanisms in the regulation of insulin resistance,"MolecularMedicine, vol. 14, no. 3-4, pp. 222-231, 2008.
60. R. Wolk, A. Deb, N. M. Caplice, and V. K. Somers, "Leptin receptor and functional effects of leptin in human endothelial progenitor cells,"Atherosclerosis, vol. 183, no. 1,pp. 131-139, 2005.
61. M. R. Schroeter, M. Leifheit, P. Sudholt et al., "Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion," Circulation Research, vol. 103, no. 5, pp. 536-544, 2008.
62. T. Thum, D. Fraccarollo, S. Thum et al., "Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 748-754, 2007.
63. S. A. Sorrentino, F.H. Bahlmann, C. Besler et al., "Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone," Circulation, vol. 116, no. 2, pp. 163-173, 2007.
64. P. M. Humpert, R. Neuwirth, M. J. Battista et al., "SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes," Diabetes Care, vol. 28, no. 4, pp. 934-936, 2005.
65. P. M.Humpert, Z. Djuric,U. Zeuge et al., "Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling," Molecular Medicine, vol. 14, no. 5-6, pp. 301-308, 2008.
66. S.Möbius-Winkler, A. Linke, V. Adams, G. Schuler, and S. Erbs, "How to improve endothelial repair mechanisms: the lifestyle approach," Expert Review of CardiovascularTherapy, vol. 8, no. 4, pp. 573-580, 2010.
67. K. A. Volaklis, S. P. Tokmakidis, and M. Halle, "Acute and chronic effects of exercise on circulating endothelial progenitor cells in healthy and diseased patients," Clinical Research in Cardiology, vol. 102, no. 4, pp. 249-257, 2013.
68. J.-S. Wang, M.-Y. Lee, H.-Y. Lien, and T.-P. Weng, "Hypoxic exercise training improves cardiac/muscular hemodynamics and is associated with modulated circulating progenitor cells in sedentarymen," International Journal of Cardiology, vol. 170, no. 3, pp. 315-323, 2014.
69. U. Laufs, A. Urhausen, N. Werner et al., "Running exercise of different duration and intensity: effect on endothelial progenitor cells in healthy subjects," European Journal of Cardiovascular Prevention and Rehabilitation, vol. 12, no. 4, pp. 407-414, 2005.
70. M. Sandri, V. Adams, S. Gielen et al., "Effects of exercise and ischemia on mobilization and functional activation of bloodderived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies," Circulation, vol. 111, no. 25, pp. 3391-3399, 2005.
71. M. Keith, M. A. Kuliszewski, C. Liao et al., "A modified portfolio diet complements medical management to reduce cardiovascular risk factors in diabetic patients with coronary artery disease," Clinical Nutrition, 2014.
72. V. Spigoni, C. Lombardi, M. Cito et al., "N-3 PUFA increase bioavailability and function of endothelial progenitor cells," Food & Function, vol. 5, no. 8, pp. 1881-1890, 2014.
73. J. Turgeon, S. Dussault, F. Maingrette et al., "Fish oil-enriched diet protects against ischemia by improving angiogenesis, endothelial progenitor cell function and postnatal neovascularization," Atherosclerosis, vol. 229, no. 2, pp. 295-303, 2013.
74. J. M. Fernández, D. Rosado-Álvarez, M. E. Da Silva Grigoletto et al., "Moderate-to-high-intensity training and a hypocaloric Mediterranean diet enhance endothelial progenitor cells and fitness in subjects with the metabolic syndrome," Clinical Science, vol. 123, no. 6, pp. 361-373, 2012.
75. C. Marin, R. Ramirez, J. Delgado-Lista et al., "Mediterranean diet reduces endothelial damage and improves the regenerative capacity of endothelium," The American Journal of Clinical Nutrition, vol. 93, no. 2, pp. 267-274, 2011.
76. B. Hibbert, T. Simard, F. D. Ramirez et al., "The effect of statins on circulating endothelial progenitor cells in humans: a systematic review," Journal of Cardiovascular Pharmacology, vol. 62, no. 5, pp. 491-496, 2013.
77. M. Vasa, S. Fichtlscherer, K. Adler et al., "Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease," Circulation, vol. 103, no. 24, pp. 2885-2890, 2001.
78. N. del Papa, M. Cortiana, C. Vitali et al., "Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis," The Journal of Rheumatology, vol. 35, no. 7, pp. 1323-1328, 2008.
79. P. E.Westerweel, F. L. J. Visseren,G.R.Hajer et al., "Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ ezetimibe combination therapy," European Heart Journal, vol. 29, no. 22, pp. 2808-2817, 2008.
80. A. E. P. Pesaro, C. V. Serrano Jr., M. Katz et al., "Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells," Journal of Cardiovascular Pharmacology and Therapeutics, vol. 18, no. 5, pp. 447-452, 2013.
81. B. Hibbert, X. Ma, A. Pourdjabbar et al., "Pre-procedural Atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries," PLoS ONE, vol. 6, no. 1, Article ID e16413, 2011.
82. Ç. Baran, S. Durdu, K. Dalva et al., "Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial," Stem Cell Reviews and Reports, vol. 8, no. 3, pp. 963-971, 2012.
83. T. Sobrino, M. Blanco, M. Pérez-Mato, M. Rodríguez-Yáñez, and J. Castillo, "Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase," European Journal of Neurology, vol. 19, no. 12, pp. 1539-1546, 2012.
84. B. Huang, Y. Cheng, Q. Xie et al., "Effect of 40mg versus 10mg of atorvastatin on oxidized low-density lipoprotein, highsensitivity c-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy," Clinical Cardiology, vol. 35,no. 2, pp. 125-130, 2012.
85. C. Spadaccio, F. Pollari, A. Casacalenda et al., "Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study," Journal of Cardiovascular Pharmacology, vol. 55, no. 1, pp. 30-38, 2010.
86. A. M. Leone, S. Rutella, M. B. Giannico et al., "Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acutemyocardial infarction: statins for regeneration after acute myocardial infarction and PCI (STRAP) trial," International Journal of Cardiology, vol. 130, no. 3, pp. 457-462, 2008.
87. L. Lu, J.-Z. Zhou, L. Wang, and T.-X. Zhang, "Effects of Xuezhikang and Pravastatin on circulating endothelial progenitor cells in patients with essential hypertension," Chinese Journal of Integrative Medicine, vol. 15, no. 4, pp. 266-271, 2009.
88. G.Paradisi,M. Bracaglia, F. Basile et al., "Effect of pravastatinon endothelial function and endothelial progenitor cells in healthy postmenopausal women," Clinical and Experimental Obstetrics and Gynecology, vol. 39, no. 2, pp. 153-159, 2012.
89. D. Tousoulis, I. Andreou, M. Tsiatas et al., "Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress," Atherosclerosis, vol. 214, no. 1, pp. 151-157, 2011.
90. S. Erbs, E. B. Beck, A. Linke et al., "High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling-results from a randomized, double-blind, and placebocontrolled study," International Journal of Cardiology, vol. 146, no. 1, pp. 56-63, 2011.
91. O. Yoshida, T. Kondo, Y. Kureishi-Bando et al., "Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers," Circulation Journal, vol. 74, no. 1, pp. 195-202, 2010.
92. A. O. Spiel, F. B. Mayr, J. M. Leitner, C. Firbas,W. Sieghart, and B. Jilma, "Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation," Thrombosis Research, vol. 123, no. 1, pp. 108-113, 2008.
93. M. Hristov, C. Fach, C. Becker et al., "Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment," Atherosclerosis, vol. 192, no. 2, pp. 413-420, 2007.
94. C.Werner,M. Baumhäkel, K. K. Teo et al., "RAS blockadewith ARB and ACE inhibitors: current perspective on rationale and patient selection," Clinical Research in Cardiology, vol. 97, no. 7, pp. 418-431, 2008.
95. F. H. Bahlmann, K. De Groot, O. Mueller, B. Hertel, H. Haller, and D. Fliser, "Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists," Hypertension, vol. 45, no. 4, pp. 526-529, 2005.
96. T. Sugiura, T. Kondo, Y. Kureishi-Bando et al., "Nifedipine improves endothelial function: role of endothelial progenitor cells," Hypertension, vol. 52, no. 3, pp. 491-498, 2008.
97. C. de Ciuceis, A. Pilu, D. Rizzoni et al., "Effect of antihypertensive treatment on circulating endothelial progenitor cells in patients with mild essential hypertension," Blood Pressure, vol. 20, no. 2, pp. 77-83, 2011.
98. F. Cacciatore, G. Bruzzese, D. F. Vitale et al., "Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients," European Journal of Clinical Pharmacology, vol. 67, no. 9, pp. 877-883, 2011.
99. J. Y. Sun, L. Zhai, Q. L. Li et al., "Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in type 2 diabetic patients," Clinics, vol. 68, no. 5, pp. 665-673, 2013.
100. T. Q. Min, C. J. Zhu, W. X. Xiang, Z. J. Hui, and S. Y. Peng, "Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patientswith stable coronary artery disease," Cardiovascular Drugs and Therapy, vol. 18, no. 3, pp. 203-209, 2004.
101. E. Cangiano, J. Marchesini, G. Campo et al., "ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patientswith acute coronary syndromes,"The AmericanJournal of CardiovascularDrugs, vol. 11,no. 3, pp. 189-198, 2011.
102. I. Porto, L. di Vito, G. L. de Maria et al., "Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome," The American Journal of Cardiology, vol. 103, no. 11, pp. 1500-1505, 2009.
103. F. Pelliccia, V. Pasceri, C. Cianfrocca et al., "Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebocontrolled study," Atherosclerosis, vol. 210, no. 2, pp. 510-515, 2010.
104. H. Tan, X. Li, W. Chen et al., "Effects of losartan on the mobilization of endothelial progenitor cells and improvement of endothelial function," Annals of Clinical and Laboratory Science, vol. 43, no. 4, pp. 402-406, 2013.
105. R. Suzuki, N. Fukuda, M. Katakawa et al., "Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension," The American Journal of Hypertension, vol. 27, no. 5, pp. 695-701, 2014.
106. A.-M. Kampoli, D. Tousoulis, Z. Pallantza et al., "Comparable effects of pioglitazone and perindopril on circulating endothelial progenitor cells, inflammatory process and oxidative stress in patients with diabetes mellitus," International Journal of Cardiology, vol. 157, no. 3, pp. 413-415, 2012.
107. Y.-F. Liao, L.-L. Chen, T.-S. Zeng et al., "Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes," Vascular Medicine, vol. 15, no. 4, pp. 279-285, 2010.
108. L.-L. Chen, Y.-F. Liao, T.-S. Zeng, F. Yu, H.-Q. Li, and Y. Feng, "Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients," Endocrine, vol. 38, no. 2, pp. 266-275, 2010.
109. L.-L. Chen, F. Yu, T.-S. Zeng, Y.-F. Liao, Y.-M. Li, and H.-C. Ding, "Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes," European Journal of Pharmacology, vol. 659, no. 2-3, pp. 296-301, 2011.
110. C. Werner, C. H. Kamani, C. Gensch, M. Böhm, and U. Laufs, "The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance," Diabetes, vol. 56, no. 10, pp. 2609-2615, 2007.
111. C.-H.Wang, M.-K. Ting, S.Verma et al., "Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus," The AmericanHeart Journal, vol. 152, no.6,pp. 1051.e1-1051.e8, 2006.
112. H.Makino, S. Okada, A. Nagumo et al., "Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients," Diabetes Research and Clinical Practice, vol. 81, no. 3, pp. 327-330, 2008.
113. K. Esposito, M. I. Maiorino, C. Di Palo et al., "Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes - a randomized controlled trial," Diabetes, Obesity and Metabolism, vol. 13, no. 5, pp. 439-445, 2011.
114. G. P. Fadini, E. Boscaro, M. Albiero et al., "The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patientswith type 2 diabetes: possible role of stromal-derived factor-1α," Diabetes Care, vol. 33, no. 7, pp. 1607-1609, 2010.
115. K. Nakamura, H. Oe, H. Kihara et al., "DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study," Cardiovascular Diabetology, vol. 13, no. 1, p. 110, 2014.
116. G. P. Fadini, S.V. deKreutzenberg,V.Mariano et al., "Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine," Diabetes, Obesity and Metabolism, vol. 13, no. 8, pp. 718-725, 2011.
117. F. Pistrosch, K. Herbrig, U. Oelschlaegel et al., "PPARγ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells," Atherosclerosis, vol. 183, no. 1, pp. 163-167, 2005.
118. H.-F. Zhang, L. Wang, H.-J. Yuan et al., "Ppar-γ agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow," Cell Biology International, vol. 37, no. 5, pp. 430-435, 2013.
119. X. Xiao-Yun, M. Zhao-Hui, C. Ke, H. Hong-Hui, and X. Yan-Hong, "Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation," Medical Science Monitor, vol. 17, no. 2, pp. BR35-BR41, 2011.
120. J. Papak and D. Kansagara, "Management of hyperglycemia in a hospitalized patient with diabetes mellitus and cardiovascular disease," The American Journal of Cardiology, vol. 110, no. 9, supplement, pp. 24B-31B, 2012.
121. K. Strehlow, N. Werner, J. Berweiler et al., "Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation," Circulation, vol. 107, no. 24, pp. 3059-3065, 2003.
122. A. Iwakura, C. Luedemann, S. Shastry et al., "Estrogenmediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury," Circulation, vol. 108, no. 25, pp. 3115-3121, 2003.
123. T. J. Povsic, S. S. Najjar, K. Prather et al., "EPC mobilization after erythropoietin treatment in acute ST-elevationmyocardial infarction: the REVEAL EPC substudy," Journal of Thrombosis andThrombolysis, vol. 36, no. 4, pp. 375-383, 2013.
124. N. J. Leeper,A. L.Hunter, and J. P.Cooke, "Stemcell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells," Circulation, vol. 122, no. 5, pp. 517-526, 2010.
125. G. Spinetti, N. Kraenkel, C. Emanueli, and P. Madeddu, "Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies," Cardiovascular Research, vol. 78, no. 2, pp. 265-273, 2008.
126. T. Asahara and A. Kawamoto, "Endothelial progenitor cells for postnatal vasculogenesis,"TheAmerican Journal of Physiology-Cell Physiology, vol. 287, no. 3, pp. C572-C579, 2004.